Isaac Scientific Publishing


Natural Complexes Are More Effective in Neuroprotection than Single Antioxidants

Download PDF (308.4 KB) PP. 1 - 8 Pub. Date: November 3, 2018



  • Sergei A. Talanov
    Department of Blood Circulation Physiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine
  • Vladimir A. Maisky
    Department of Brain Physiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine
  • Olena A. Fedorenko*
    Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK


Antioxidants can delay or prevent apoptosis of neurons in animal Parkinson’s disease models. The aim of this study was to find out which of known antioxidants is the most effective in neuroprotection. Using morphological and behavioral tests in rats treated with different antioxidants, correlations between extension of dopaminergic neurons lesions in the mesolimbic and nigrostriatal midbrain after 6-hydroxydopamine (6-OHDA) neurotoxin injections were investigated. We found that some antioxidants were capable in preventing 6-OHDA-induced apoptosis of neurons to a considerable extent. The efficacy of the tested antioxidants corresponded to the following sequence: wheat malt>Melatonin>Trolox>Q10. We conclude that though Melatonin has a significant protective effect preventing the 6-OHDA-induced apoptosis of neurons in the midbrain structures, the natural complexes derived from food, such as wheat malt, are more effective in neuroprotection than commercial preparations of separate pure antioxidants. Natural extracts of antioxidants may be beneficial to prevent or delay age-related neurodegenerative diseases in humans.


Parkinsonism, 6-hydroxydopamine, rat model, antioxidants


[1] C.C. Chiueh, G. Krishna, P. Tulsi, T. Obata, K. Lang, S.J. Huang, and D.L. Murphy, “Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effect of MPP+,” Free Rad. Biol. Med., 13, 581-583, 1992.

[2] A. Napolitano, P. Manini, and M. d'Ischia, “Oxidation chemistry of catecholamines and neuronal degeneration: an update,” Curr. Med. Chem., 18, 1832-1845, 2011.

[3] P. Jenner, “Oxidative stress in Parkinson's disease,” Ann. Neurol., 53, 26-36, 2003.

[4] Y. Aluf, J. Vaya, S. Khatib, Y. Loboda, S. Kizhner, and J.P. Finberg, “Specific oxidative stress profile associated with partial striatal dopaminergic depletion by 6-hydroxydopamine as assessed by a novel multifunctional marker molecule,” Free Radic. Res., 44, 635-644, 2010.

[5] J. Han, F.C Cheng, Z. Yang, and G. Dryhurst, “Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implication to Parkinson's disease,” J. Neurochem., 73, 1683-1695, 1999.

[6] J.W. Langston, “MPTP neurotoxity: an overview and characterization of phases of toxicity,” Life Science, 36, 201-206, 1985.

[7] P. Foley, and P. Riederer, “Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease,” J. Neurol., 247 (S2), 82-94, 2000.

[8] V.F. Sagach, O.V. Bazilyuk, N.N. Oleshko, V.A. Maisky, A. Costa, and E. Martignoni, “Mesostriatal lesions and endothelial fumction: effects of forced movements and hypoxia on levels of circulating endothelins,” Neurophysiology 30, 18-24, 1998.

[9] V.A. Maisky, N.N. Oleshko, O.V. Bazilyuk, S.A. Talanov, V.F. Sagach, and O. Appenzeller, “Fos and nitric oxide synthase in rat brain with chronic mesostriatal dopamine deficiency: effects of nitroglycerin and hypoxia,” Parkinsonism Relat. Disord., 8, 261-270, 2002.

[10] H.C. Curtius, M. Wolfensberger, B. Steinmann, U. Redweik, and J. Siegfried, “Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus,” J. Chromatography, 99, 529-540, 1974.

[11] R. Andrew, D.G. Watson, S.A. Best, J.M. Midgley, H. Wenlong, and R.K. Petty, “The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls,” Neurochem. Res., 18, 1175-1177, 1993.

[12] J.C. Mayo, R.M. Sainz, H. Uria, I. Antolin, M.M. Esteban, and C. Rodriguez, “Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease,” J. Pineal. Res. 3, 179-192, 1998.

[13] U. Ungerstedt, “Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system,” Acta Physiol. Scand., 367, 95-122, 1997.

[14] S.A. Talanov, N.N. Oleshko, M.N. Tkachenko, and V.F. Sagach, “Pharmacoprotective influences on different links of the mechanism underlying 6-hydroxydopamine-induced degeneration of nigrostriatal dopaminergic neurons,” Neurophysiology, 38, 128-133, 2006.

[15] L.T. Pellegrino, A.S. Pellegrino, and A.T. Cushman, “A stereotaxic atlas of the rat brain,” New York: Plenum Press, 1979.

[16] D. Kirik, C. Rosenblad, and A. Bj?rklund, “Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat,” Exp. Neurol., 152, 259-277, 1998.

[17] G. Paxinos, and C. Watson, “The rat brain in stereotaxic coordinated,” New York: Academic Press, 1997.

[18] F.L. Crane, “Biochemical functions of coenzyme Q10,” J. Am. Coll. Nutr., 20, 591-598, 2001.

[19] I.P. Hargreaves, A. Lane, and P.M. Sleiman, “The coenzyme Q10 status of the brain regions of Parkinson's disease patients,” Neurosci. Lett., 447, 17-19, 2008.

[20] R. Ricciarelli, F. Argellati, M.A. Pronzato, and C. Domenicotti, “Vitamin E and neurodegenerative diseases,” Mol. Aspects Med., 28, 591-606, 2007.

[21] A. Azzi, E. Aratri, D. Boscoboinik, S. Clément, N.K. Ozer, R. Ricciarelli, and S. Spycher, “Molecular basis of alpha-tocopherol control of smooth muscle cell proliferation,” Biofactors, 7, 3-14, 1998.

[22] D.A. Butterfield, A. Castegna, J. Drake, G. Scapagnini, and V. Calabrese, “Vitamin E and neurodegenerative disorders associated with oxidative stress,” Nutr. Neurosci., 5, 229-239, 2002.

[23] V.F. Sagach, M. Scrosati, J. Fielding, G. Rossoni, C. Galli, and F.Visioli, “The water-soluble vitamin E analogue Trolox protects against ischaemia/reperfusion damage in vitro and ex vivo. A comparison with vitamin E,”Pharmacol. Res., 45, 435-439, 2002.

[24] S.C. Bondy, and E.H. Sharman, “Melatonin and the aging brain,” Neurochem. Int., 50, 571-580, 2007.

[25] E.H. Sharman, S.C. Bondy, K.G. Sharman, D. Lahiri, C.W. Cotman, and V.M. Perreau, “Effects of melatonin and age on gene expression in mouse CNS using microarray analysis,” Neurochem. Int., 50, 336-344, 2007.

[26] S.C. Bondy, H. Li, J. Zhou, M. Wu, J.A. Bailey, and D.K. Lahiri, “Melatonin alters age-related changes in transcription factors and kinase activation,” Neurochem. Res., 35, 2035-2042, 2010.

[27] S.L. Albarracin, B. Stab, Z. Casas, J.J. Sutachan, I. Samudio, J. Gonzalez, L. Gonzalo, F. Capani, L.Morales, and G.E. Barreto, “Effects of natural antioxidants in neurodegenerative disease,” Nutr. Neurosci., 15, 1-9, 2012.

[28] B. Zhao, “Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease,” Neurochem. Res., 34, 630-638, 2009.